An international research team led by the Helmholtz Center for Infection Research (HZI) has discovered a new strategy used by ...

Researchers at Children's Hospital of Philadelphia (CHOP) have found that in rare instances, variants responsible for SYNGAP1 ...

Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click for more on LLY and VERV.

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular ...

Heterozygous Genetic Diseases In some types of genetic diseases, heterozygous genes almost always cause the disease. In diseases caused by dominant genes, a person needs only one copy of a ...

YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH ...

The global Phase 3 LIBerate program enrolled a diverse population of over 2,900 patients with CVD, without CVD at very high and high risk for CVD, including heterozygous and homozygous familial ...

Learn about the causes, symptoms, and treatment of heterozygous familial hypercholesterolemia, a disease that causes you to have very high cholesterol levels.

– Confirms Sufficient Data to Complete Phase 2 Clinical Study Enrollment and Advance to Phase 3 Studies in Both Heterozygous and Homozygous Familial Hypercholesterolemia – – Establishes ...

Heterozygous patients displayed lower levels of CRP, SAA, S100A8/A9, and S100A12 during inactive and subclinical phases compared with homozygous or compound heterozygous patients. Among heterozygous ...